ArticleFrontiers in cardiovascular medicine2026
TRI-SCORE based risk stratification across contemporary treatment strategies for isolated tricuspid regurgitation: a multicenter retrospective analysis.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The TRI-SCORE is a disease-specific risk model developed to predict outcomes after isolated tricuspid valve surgery. Although its prognostic value has been demonstrated across contemporary treatment strategies, independent external validation in multicenter cohorts across a broader clinical and etiological spectrum remains limited. We evaluated the prognostic performance of the TRI-SCORE in patients with isolated ≥ moderate tricuspid regurgitation (TR) treated with medical therapy, surgery, or transcatheter tricuspid edge-to-edge repair (T-TEER). Methods: In this retrospective multicenter study, 104 patients with isolated ≥ moderate TR treated between 2010 and 2024 were included. Patients underwent medical therapy ( Results: The median age was 77.0 years (IQR, 69.8-83.0), 62% of patients were women, and the median follow-up was 45 months (IQR, 27-63). During follow-up, all-cause mortality occurred in 37 (36%), and the composite endpoint in 40 (38%). One-year all-cause mortality increased across TRI-SCORE categories (7%, 13%, and 33% in the low-, intermediate-, and high-risk groups, respectively; Conclusions: In this multicenter real-world cohort of patients with isolated ≥ moderate TR, the TRI-SCORE provided independent prognostic information across medical therapy, surgery, and T-TEER. These findings provide external validation of the TRI-SCORE in a multicenter cohort representing a broader clinical and etiological spectrum than previously evaluated, supporting its use for baseline risk stratification across contemporary management strategies. Treatment comparisons should be interpreted cautiously because of the observational study design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.